Deqi Pharmaceuticals Shaoxing production base is completed to accelerate the launch of innovative drugs in China

On May 14, the inauguration ceremony of the Shaoxing production base of Deqi Pharmaceutical Co.
, Ltd.
was successfully held in the Binhai New City Life and Health Technology Industrial Park
.

The completion of the base has laid a solid foundation for the commercial production of Deqi Pharmaceutical solid preparation products, marking that Deqi Pharmaceutical has moved towards an innovative pharmaceutical company in the entire industry chain integrating early R&D, clinical research, production and commercialization

Dr.
Mei Jianming, the founder, chairman and CEO of Deqi Pharmaceuticals, said, “It took Deqi Pharmaceuticals to deploy 12 innovative drugs covering 4 major diseases in three years, and to build a commercial solid preparation production base within one year.
, We are
practicing'China Innovation' and'China Speed' .

The production base is a key part of Deqi Pharmaceutical's promotion of commercialization, and it is also an important pillar for Deqi Pharmaceutical to realize the value of the entire production chain

Dr.
Shan Bo, Chief Scientific Officer of Deqi Pharmaceuticals, said: “Drug production is located in the downstream of the Deqi pharmaceutical industry chain and is an important hub for the commercialization of clinical research results
.

The completion of the base has accelerated our R&D and commercialization steps.

High-standard construction, establish a model of high-quality base

Deck Pharma's Shaoxing production base covers an area of ​​16,300 square meters
.

As of today, the base has completed plant decoration, installed supporting public facilities for solid preparation products, equipped with a solid preparation commercial packaging production line that meets international GMP standards, and established a QC laboratory for material and product inspection

Since the start of the first phase of the project in June 2020, Deqi Pharmaceuticals has adopted the quality policy of "high-quality products, Deqi's mission, caring for patients, and quality first", rationally dividing production and storage space, strictly controlling the construction links, and ensuring all-round assurance The quality of the finished product
.

In the construction process, Deqi Pharmaceuticals has established a scientific and professional quality management system with domestic first-class design units and engineering companies, and selected business partners based on international standards to promote the high-standard construction of the base

Focus on the needs of patients, focus on policies to achieve the implementation of innovative ideas

As a leader in innovative tumor therapy, Deqi Pharmaceutical focuses on the research and development and commercialization of the first, unique and best-in-class drugs
.

The company has established a highly differentiated product pipeline with the strategic orientation of "union and complementarity" and has 12 innovative drugs that can be synergistic

Zhejiang Shaoxing Binhai New Area, where the production base is located, is a highland for the transformation of scientific and technological achievements in the Yangtze River Delta
.

Binhai New Area will build a high-tech industrial cluster by connecting with the Shanghai International Science and Technology Innovation Center, undertaking high-tech and high-end talent overflow

Taking advantage of preferential policies such as the "14th Five-Year Plan", Deqi Pharmaceuticals has made considerable progress in the pharmaceutical field, and the value of the entire industry chain is gradually emerging
.

In the future, Deqi Pharmaceuticals will continue to rely on the high-quality resources and innovation platform provided by the government, and integrate the spirit of excellence and continuous innovation into the development of each product and the innovation of each technology, in order to promote the development and upgrading of China's new drug research.